Last updated: June 4, 2026
Omnipred is a brand name for prednisolone acetate ophthalmic products in the US market. The supplier landscape is largely determined by (1) the specific marketed strength and dosage form (solution vs suspension), (2) whether the product is marketed as a generic under the same NDA/ANDA family, and (3) Orange Book exclusivity/patent status that shapes which manufacturers can supply without IP exposure. Without the exact Omnipred label configuration (strength, dosage form, pack size, and market), a complete supplier list cannot be produced accurately.
What manufacturers supply Omnipred (prednisolone acetate ophthalmic) in the US market?
Featured-supplier intelligence for Omnipred depends on the FDA application and product listing behind the Omnipred label. Supplier identification typically maps to one or more of the following:
- Drug substance manufacturers supplying prednisolone acetate
- Drug product manufacturers filling and finishing the ophthalmic formulation
- Labeler/distributors responsible for the marketed NDA/ANDA entry
Because the Omnipred label can correspond to different strengths/dosage formats and potentially different application families over time, identifying “suppliers for Omnipred” requires tying the brand to the correct FDA product record(s) and then extracting the listed manufacturers.
Which FDA fields determine the true “supplier” for Omnipred?
For each finished product listing, supplier roles are derived from:
- Labeler (applicant) name for the marketed product
- Manufacturer(s) / packager(s) for finished dosage form
- NDC-level listing (strength and dosage form specific)
- Orange Book listing (if any) for the associated NDA/ANDA
What do typical ophthalmic supply chains look like for prednisolone acetate?
Common supply-chain structures for ophthalmic steroids include:
- External synthesis and crystallization of prednisolone acetate by specialized chemical manufacturers
- Formulation in sterile ophthalmic systems with controlled particle size (for suspensions) and validated sterilization/aseptic processes
- Packaging in dropper bottles with validated closure systems for ocular dosing
This structure means “supplier” can refer to multiple firms across different stages, not a single company.
How many companies can legally manufacture Omnipred prednisolone acetate under FDA approvals?
The number of legal manufacturers is governed by:
- Whether Omnipred’s active ingredient and dosage form are covered by unexpired patents/exclusivities for the specific FDA application family
- Whether generic or authorized-entrant manufacturers have ANDA approvals for the same formulation parameters
- Whether the product is a standalone NDA (fewer entrants) or an established generic (more entrants)
What is the Orange Book status of Omnipred?
Orange Book status is the gating factor for entry and for assessing patent-ownership risk, including:
- Composition-of-matter patents
- Formulation patents
- Method-of-use patents (less common for simple ophthalmic steroids but can exist)
- Oral/suspension-specific manufacturing patents
- Exclusivity blocks tied to approval history
Without the exact Omnipred application record tied to the user’s intended configuration, the Orange Book status cannot be stated accurately.
What generic ANDA manufacturers are potential competitors to Omnipred?
If Omnipred is not protected by exclusivity for a given strength/dosage form, the market typically includes:
- Multiple ANDA sponsors for prednisolone acetate ophthalmics
- Authorized generics tied to earlier agreements
- Different manufacturer plants even when the labeler differs
A complete “supplier list” therefore has to be constructed by:
- extracting the NDC-to-application mapping for Omnipred,
- identifying the ANDAs or NDAs that correspond to that configuration,
- then enumerating the approved manufacturers for those applications.
Which drug substance suppliers provide prednisolone acetate for ophthalmic use?
Prednisolone acetate drug substance supply usually comes from a set of specialized API makers serving ophthalmic and corticosteroid markets. However, Omnipred-specific attribution requires:
- Finished-product labeler/manufacturer disclosure mapping to the approved API supplier(s) where available
- Inspection of FDA drug application labeling/manufacturing descriptions for the corresponding NDA/ANDA
Without the specific Omnipred application record, an Omnipred-anchored API supplier list would risk naming non-applicable firms.
What manufacturing sites supply Omnipred: finished dosage form or contract manufacturing?
For marketed ophthalmics, finished dosage form supply can involve:
- In-house manufacturing by the labeler/applicant
- Contract manufacturing organizations (CMOs) filling and finishing under the applicant’s NDA/ANDA
The supplier answer typically changes by:
- Sterile processing site
- Suspension manufacturing controls (for particle size and suspension stability)
- Packaging line constraints (dropper-bottle sterilization and fill)
A supplier list must be assembled from the finished-product manufacturing site(s) for the specific FDA listing.
When can new suppliers enter Omnipred prednisolone acetate: exclusivity and patent timelines?
Entry timing is dictated by the last of:
- Patent expirations listed in the Orange Book for the relevant NDA/ANDA
- Regulatory exclusivities (if any) tied to the approval history
- Ongoing litigation outcomes that can delay generic launch through settlement terms
A correct timeline requires the exact Orange Book and exclusivity record for the Omnipred configuration.
What patent litigation affects Omnipred supply?
For ophthalmic steroid brands, litigation risk can arise through:
- Paragraph IV ANDA challenges
- Settlement agreements that delay launch
- Injunctions affecting specific dosage strengths
A litigation-driven supplier restriction depends on which ANDAs are challenged and which patents are asserted. Without the exact application and Orange Book mapping, litigation-driven supply impacts cannot be enumerated.
How do Omnipred suppliers compare with other prednisolone acetate ophthalmic brands?
Market supply comparisons typically come down to:
- Number of ANDA entrants
- Device and container format (bottle vs unit-dose, closure type)
- Differences in suspension particle size (for suspensions) and viscosity (for solutions)
- Manufacturing facility diversity across regions
A substantiated comparison again requires the Omnipred-specific NDC and FDA application mapping.
Key Takeaways
- “Suppliers for Omnipred” depends on the exact prednisolone acetate ophthalmic configuration (strength and dosage form) and the corresponding FDA NDA/ANDA record.
- Supplier identification requires Orange Book and FDA listing mapping to enumerate labelers and manufacturing sites.
- Without the specific Omnipred product record, a complete, accurate supplier list cannot be produced.
FAQs
-
How do I identify the finished dosage manufacturer for Omnipred in the US?
Use the Omnipred NDC to map to its FDA application listing, then extract the “manufacturer/packager” fields for that listing.
-
Do prednisolone acetate ophthalmic generics have multiple manufacturing sites under one ANDA?
Yes. An ANDA can authorize more than one site for manufacturing, depending on the submission and approval.
-
Can an API supplier be identified from Omnipred labeling?
Often not directly from consumer label text; mapping requires the FDA application manufacturing disclosure for the relevant NDA/ANDA.
-
What determines whether new entrants can supply Omnipred quickly?
Orange Book patent and exclusivity status for the specific strength/dosage form, plus any Paragraph IV litigation/settlement constraints.
-
Are there common supplier bottlenecks for ophthalmic steroid products?
Sterile manufacturing capacity, suspension stability/particle-size controls (for suspensions), and packaging/closure line validation are typical constraints.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products.
